{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:16:25Z","timestamp":1783494985185,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inflammatory arthritis comprises lifelong conditions, such as rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis that require long-term treatment and regular monitoring. People with inflammatory arthritis usually require long-term treatment with immune-suppressing medications and are typically reviewed in outpatient clinics every 6\u201312 months, accounting for 1.3 million appointments\/year in the UK. The National Health Service (NHS) is implementing a move to patient-initiated follow-up (PIFU) where patients request appointments as required. To date, there are small studies of PIFU in rheumatoid arthritis and none in other arthritis. Research is required to configure services to optimise outcomes, inform patients and clinicians of the effectiveness and safety of PIFU and ensure that suitable patients are selected for this pathway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>TaILOR is a two-arm, pragmatic, parallel group, superiority, randomised controlled clinical study, with an embedded qualitative study conducted across 32 secondary care NHS sites in the UK. Eligible participants must be 18 years or older, with stable inflammatory arthritis, and diagnosed for at least 2 years. In addition, they need to be suitable for PIFU based on NHS England guidance and in the opinion of their usual care team; 438 participants will be randomised in a 1:1 ratio to either PIFU, with a fixed 24-month safety net appointment, or standard care, with 6\u201312 monthly follow-up visits. The trial includes an internal recruitment feasibility pilot, as well as health economics and qualitative analyses. The primary outcome will assess the effectiveness of PIFU compared to standard care on musculoskeletal quality of life at 24 months. Secondary outcomes include quality of life, incremental costs, cost-effectiveness, treatment escalation, disease activity, flares, patient confidence in interactions with their clinical team (patient perceived efficacy in patient-physician interactions), depression and acceptability of PIFU (via qualitative interviews).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>As a national multi-centre study, this will provide the definitive evaluation of PIFU for inflammatory arthritis. Qualitative analysis will generate insights into individual and contextual factors affecting the acceptability of PIFU, identify variation across sites or between patients and provide information on how this can be addressed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ISRCTN ISRCN10480648. Registered on 17 January 2025.<\/jats:p>\n                    <jats:p>Protocol version {2}: Version 3.0 date 04 Dec 2025.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-026-09868-0","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:35:19Z","timestamp":1783128919000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TaILOR: a randomised trial to compare the clinical and cost-effectiveness of a patient-initiated follow-up (PIFU) strategy compared to standard care pathways in people with inflammatory arthritis: a study protocol"],"prefix":"10.1186","volume":"27","author":[{"given":"Gretchen","family":"Brewer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Mwema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Abhishek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailsa","family":"Bosworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bundy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Conroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Dakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Dures","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Eddison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Galloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Jennings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Lall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"MacPhie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Norton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Raleigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mel Brooke","family":"Turfrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"key":"9868_CR1","unstructured":"Versus Arthritis. The State of Musculoskeletal Health 2021, Versus Arthritis. 2021."},{"key":"9868_CR2","volume-title":"The NHS Plan: A plan for investment, a plan for reform","author":"NHS England NHS Improvement","year":"2020","unstructured":"NHS England NHS Improvement. The NHS Plan: A plan for investment, a plan for reform. London: London, Stationary Office; 2020."},{"key":"9868_CR3","unstructured":"NHS England. NHS England, Patient initiated follow-up. https:\/\/www.england.nhs.uk\/outpatient-transformation-programme\/patient-initiated-follow-up-giving-patients-greater-control-over-their-hospital-follow-up-care\/. Accessed 19 July 2024."},{"key":"9868_CR4","unstructured":"NHS England and NHS Improvement. 2022\/23 priorities and operational planning guidance. 2021."},{"key":"9868_CR5","unstructured":"NHS England. Reforming Elective Care for Patients. 2025. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2023\/04\/reforming-elective-care-for-patients.pdf"},{"key":"9868_CR6","doi-asserted-by":"crossref","unstructured":"NHS England. Fit for the future \u2013 The 10 year health plan for England. 2025. https:\/\/www.gov.uk\/government\/publications\/10-year-health-plan-for-england-fit-for-the-future\/fit-for-the-future-10-year-health-plan-for-england-executive-summary.","DOI":"10.12968\/jokc.2025.10.5.212"},{"key":"9868_CR7","unstructured":"NHS England and NHS Improvement. Implementing Patient Initiated Follow-Up (PIFU) in adult rheumatology services. London; 2021."},{"key":"9868_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010763.pub2","author":"R Whear","year":"2020","unstructured":"Whear R, Thompson-Coon J, Rogers M, Abbott RA, Anderson L, Ukoumunne O, et al. Patient-initiated appointment systems for adults with chronic conditions in secondary care. Cochrane Database Syst Rev. 2020. https:\/\/doi.org\/10.1002\/14651858.CD010763.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"9868_CR9","doi-asserted-by":"crossref","unstructured":"Hewlett S, Kirwan J, Pollock J, Mitchell K, Hehir M, Blair PS, et al. Patient initiated outpatient follow up in rheumatoid arthritis: six year randomised controlled trial. BMJ 2025 -09\u201324;330(7484).","DOI":"10.1136\/bmj.38265.493773.8F"},{"issue":"2","key":"9868_CR10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1136\/annrheumdis-2012-202695","volume":"73","author":"J Primdahl","year":"2014","unstructured":"Primdahl J, S\u00f8rensen J, Horn HC, Petersen R, H\u00f8rslev-Petersen K. Shared care or nursing consultations as an alternative to rheumatologist follow-up for rheumatoid arthritis outpatients with low disease activity--patient outcomes from a 2-year, randomised controlled trial. Ann Rheum Dis. 2014;73(2):357\u201364.","journal-title":"Ann Rheum Dis"},{"key":"9868_CR11","doi-asserted-by":"crossref","unstructured":"Poggenborg RP, Madsen OR, Sweeney AT, Dreyer L, Bukh G, Hansen A. Patient-controlled outpatient follow-up on demand for patients with rheumatoid arthritis: a 2-year randomized controlled trial. Clin Rheumatol 2021 -03-06;40(9):3599.","DOI":"10.1007\/s10067-021-05674-y"},{"key":"9868_CR12","doi-asserted-by":"publisher","unstructured":"Fredriksson C, Ebbevi D, Waldheim E, Lindblad S, Ernestam S. Patient-initiated appointments compared with standard outpatient care for rheumatoid arthritis: a randomised controlled trial.\u00a0RMD Open. 2016;2(1):e000184.\u00a0https:\/\/doi.org\/10.1136\/rmdopen-2015-000184. eCollection 2016.","DOI":"10.1136\/rmdopen-2015-000184"},{"key":"9868_CR13","doi-asserted-by":"publisher","unstructured":"Alveyn E, Crowder R, Perry M, Norton S, Galloway J. Patient-initiate follow up in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology. 2024;63(Supplement 1):keae163.106.\u00a0https:\/\/doi.org\/10.1093\/rheumatology\/keae163.106.","DOI":"10.1093\/rheumatology\/keae163.106"},{"key":"9868_CR14","unstructured":"International Standard Randomised Controlled Trials Number. https:\/\/www.isrctn.com\/ISRCTN10480648. Accessed 28 November 2025."},{"key":"9868_CR15","unstructured":"British Society for Rheumatology. https:\/\/www.rheumatology.org.uk\/news\/details\/Launch-of-the-PIFU-Toolkit-Empowering-patients-in-rheumatology. Accessed 28 November 2025."},{"key":"9868_CR16","doi-asserted-by":"publisher","unstructured":"Hill JC, Kang S, Benedetto E, Myers H, Blackburn S, Smith S, et al. Development and initial cohort validation of the Arthritis Research UK Musculoskeletal Health Questionnaire (MSK-HQ) for use across musculoskeletal care pathways. BMJ Open. 2016;6(8):e012331. https:\/\/doi.org\/10.1136\/bmjopen-2016-012331.","DOI":"10.1136\/bmjopen-2016-012331"},{"key":"9868_CR17","doi-asserted-by":"publisher","unstructured":"Norton S, Ellis B, Santana Su\u00e1rez B, Schwank S, Fitzpatrick R, Price A, et al. Validation of the Musculoskeletal Health Questionnaire in inflammatory arthritis: a psychometric evaluation. Rheumatology (Oxford). 2019.;58(1):45-51. https:\/\/doi.org\/10.1093\/rheumatology\/key240.","DOI":"10.1093\/rheumatology\/key240"},{"issue":"9","key":"9868_CR18","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/S0895-4356(99)00071-2","volume":"52","author":"KW Wyrwich","year":"1999","unstructured":"Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol. 1999;52(9):861\u201373.","journal-title":"J Clin Epidemiol"},{"key":"9868_CR19","unstructured":"British Society for Rheumatology. National Early Inflammatory Arthritis - First Annual Report. 2019."},{"key":"9868_CR20","doi-asserted-by":"crossref","unstructured":"Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Journal of Pharmacology and Pharmacotherapeutics 2010 -12;1(2):100.","DOI":"10.4103\/0976-500X.72352"},{"key":"9868_CR21","doi-asserted-by":"publisher","unstructured":"Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD, et al. Reporting of patient-reported outcomes in randomized trials. JAMA. 2013;309(8):814\u201322. https:\/\/doi.org\/10.1001\/jama.2013.879.","DOI":"10.1001\/jama.2013.879"},{"key":"9868_CR22","unstructured":"StataCorp LP. https:\/\/www.stata.com. Accessed 28 November 2025."},{"key":"9868_CR23","unstructured":"International Conference on Harmonisation E9, Expert Working Group. ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. Stat Med 1999;18(15):1905\u201342."},{"key":"9868_CR24","doi-asserted-by":"publisher","unstructured":"Fereday J, Muir-Cochrane E. Demonstrating rigor using thematic analysis: a hybrid approach of inductive and deductive coding and theme development The International Journal of Qualitative Methods. 2006. https:\/\/doi.org\/10.1177\/160940690600500107","DOI":"10.1177\/160940690600500107"},{"key":"9868_CR25","doi-asserted-by":"publisher","unstructured":"Xu W, Zammit K. Applying thematic analysis to education: a hybrid approach to interpreting data in practitioner research.\u00a0Int J Qual Methods. 2020. Published online https:\/\/doi.org\/10.1177\/1609406920918810.","DOI":"10.1177\/1609406920918810"},{"key":"9868_CR26","doi-asserted-by":"publisher","unstructured":"Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework.\u00a0BMC Health Serv Res. 2017;17(1):88. https:\/\/doi.org\/10.1186\/s12913-017-2031-8.","DOI":"10.1186\/s12913-017-2031-8"},{"key":"9868_CR27","doi-asserted-by":"crossref","unstructured":"Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process evaluation of complex interventions: Medical Research Council guidance. BMJ. 2015;350(mar19 6):h1258.","DOI":"10.1136\/bmj.h1258"},{"issue":"2","key":"9868_CR28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40273-022-01218-7","volume":"41","author":"M Hernandez Alava","year":"2023","unstructured":"Hernandez Alava M, Pudney S, Wailoo A. Estimating the relationship between EQ-5D-5L and EQ-5D-3L: results from a UK population study. Pharmacoeconomics. 2023;41(2):199\u2013207.","journal-title":"Pharmacoeconomics"},{"key":"9868_CR29","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: The manual. 2022.\u00a0https:\/\/www.nice.org.uk\/process\/pmg36."},{"key":"9868_CR30","doi-asserted-by":"publisher","unstructured":"Husereau D, Drummond M, Augustovski F, De Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3-9. https:\/\/doi.org\/10.1016\/j.jval.2021.11.1351.","DOI":"10.1016\/j.jval.2021.11.1351"},{"key":"9868_CR31","doi-asserted-by":"crossref","unstructured":"Gamble C, Krishan A, Stocken D, Lewis S, Juszczak E, Dor\u00e9 C, et al. Guidelines for the content of statistical analysis plans in clinical trials. JAMA. 2017;318(23).","DOI":"10.1001\/jama.2017.18556"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09868-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09868-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09868-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T06:55:18Z","timestamp":1783493718000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09868-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9868"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09868-0","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval has been received from South East Scotland REC 01 (25\/SS\/0004). All participants will provide informed consent by completing a consent form (electronic or paper). Each trial site will obtain necessary local approvals before any participants are enrolled to the TaILOR study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Not applicable, protocol publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LCC has received grants\/research support from AbbVie, Amgen, Janssen and UCB; worked as a paid consultant for AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Enlivex, Janssen, Moonlake, Novartis, Pfizer, Proximi-T, Takeda and UCB; and has been paid as a speaker for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer and UCB.AA reports Royalties from UpToDate, lecture fees from SOBI, consulting fees from Eli Lilly, Novartis, and Alesta outside the submitted work.MP has received honoraria and speaker fees\u2009<\u00a32000 from UCB and Janssen.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {7b}"}}],"article-number":"475"}}